30 related articles for article (PubMed ID: 12673728)
1. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Lin CC; Beeram M; Rowinsky EK; Takimoto CH; Ng CM; Geyer CE; Denis LJ; De Bono JS; Hao D; Tolcher AW; Rha SY; Jolivet J; Patnaik A
Cancer Chemother Pharmacol; 2009 Dec; 65(1):167-75. PubMed ID: 19449006
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
5. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Shapiro GI; Tibes R; Gordon MS; Wong BY; Eder JP; Borad MJ; Mendelson DS; Vogelzang NJ; Bastos BR; Weiss GJ; Fernandez C; Sutherland W; Sato H; Pierceall WE; Weaver D; Slough S; Wasserman E; Kufe DW; Von Hoff D; Kawabe T; Sharma S
Clin Cancer Res; 2011 May; 17(10):3431-42. PubMed ID: 21220472
[TBL] [Abstract][Full Text] [Related]
6. Tezacitabine Hoechst Marion Roussel.
Seley KL
Curr Opin Investig Drugs; 2000 Sep; 1(1):135-40. PubMed ID: 11249589
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Gregorc V; De Braud FG; De Pas TM; Scalamogna R; Citterio G; Milani A; Boselli S; Catania C; Donadoni G; Rossoni G; Ghio D; Spitaleri G; Ammannati C; Colombi S; Caligaris-Cappio F; Lambiase A; Bordignon C
Clin Cancer Res; 2011 Apr; 17(7):1964-72. PubMed ID: 21307147
[TBL] [Abstract][Full Text] [Related]
8. Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.
Lee SJ; Gounder M; Rubin EH; Li JM; Gu Z; Thalasila A; Loyer E; Kudelka AP; Verschraegen CF
Invest New Drugs; 2008 Dec; 26(6):541-51. PubMed ID: 18600301
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.
Huff SE; Winter JM; Dealwis CG
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740940
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Mannargudi MB; Deb S
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1499-1529. PubMed ID: 28624910
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer.
Flaherty KT; Stevenson JP; Gallagher M; Giantonio B; Algazy KM; Sun W; Haller DG; O'Dwyer PJ
Cancer; 2003 Apr; 97(8):1985-90. PubMed ID: 12673728
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.
Bendell JC; Eder JP; Clark JW; Fidias P; Lynch TJ; Seiden MV; Ryan DP
Cancer; 2005 May; 103(9):1925-31. PubMed ID: 15772958
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
